Shield Therapeutics plc (AIM:STX)
London
· Delayed Price · Currency is GBP · Price in GBX 2.400
-0.150 (-5.88%)
May 9, 2025, 4:35 PM GMT+1
Shield Therapeutics Revenue
In the year 2024, Shield Therapeutics had annual revenue of $32.18M USD with 145.93% growth. Shield Therapeutics had revenue of $20.05M in the half year ending December 31, 2024, with 594.90% growth.
Revenue
$32.18M
Revenue Growth
+145.93%
P/S Ratio
0.97
Revenue / Employee
$440.82K
Employees
73
Market Cap
25.00M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32.18M | 19.10M | 145.93% |
| Dec 31, 2023 | 13.09M | 7.59M | 137.95% |
| Dec 31, 2022 | 5.50M | 3.44M | 167.35% |
| Dec 31, 2021 | 2.06M | -12.12M | -85.50% |
| Dec 31, 2020 | 14.18M | 13.23M | 1,389.24% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 42.56B |
| GSK plc | 31.53B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Genus | 671.60M |
Shield Therapeutics News
- 3 months ago - UK Stock Market News: GSK, DCC, Shield Therapeutics - The Armchair Trader
- 6 months ago - Small Cap Stocks: Microsalt, Proton Motor Power, Eckoh - The Armchair Trader
- 7 months ago - Small Cap Stocks: Seascape Energy, Arkle, Mirriad - The Armchair Trader
- 4 years ago - OTC Markets Group Welcomes Shield Therapeutics PLC to OTCQX - PRNewsWire